MA (EU) number 
(Invented) 
name 
Strength  Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
Content 
(concentration) 
Pack size 
EU/1/20/1528/001  COMIRNATY   
--¹  
EU/1/20/1528/002  COMIRNATY   
--2  
EU/1/20/1528/003  COMIRNATY   
--2  
EU/1/20/1528/004  COMIRNATY   
--3 
EU/1/20/1528/005  COMIRNATY   
--3 
EU/1/20/1528/006  COMIRNATY 
--4  
EU/1/20/1528/007  COMIRNATY 
--4  
Original/Omicron 
BA.1 
Original/Omicron 
BA.1 
EU/1/20/1528/008  COMIRNATY 
--5  
EU/1/20/1528/009  COMIRNATY 
--5  
Original/Omicron 
BA.4-5  
Original/Omicron 
BA.4-5 
EU/1/20/1528/010  COMIRNATY 
EU/1/20/1528/011  COMIRNATY 
Original/Omicron 
BA.4-5 
EU/1/20/1528/012  COMIRNATY  
Original/Omicron 
BA.4-5 
--6 
--7 
--7 
Concentrate for 
dispersion for 
injection 
Dispersion for 
injection 
Intramuscular 
use 
Intramuscular 
use 
vial (glass) 
vial (glass) 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
Concentrate for 
dispersion for 
injection 
Concentrate for 
dispersion for 
injection 
Dispersion for 
injection 
Intramuscular 
use 
Intramuscular 
use 
Intramuscular 
use 
vial (glass) 
vial (glass) 
vial (glass) 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
Concentrate for 
dispersion for 
injection 
Concentrate for 
dispersion for 
injection 
Concentrate for 
dispersion for 
injection 
Intramuscular 
use 
Intramuscular 
use 
Intramuscular 
use 
vial (glass) 
vial (glass) 
vial (glass) 
0.45 ml 
(6 doses) 
2.25 ml 
(6 doses) 
2.25 ml 
(6 doses) 
1.3 ml 
(10 doses) 
1.3 ml 
(10 doses) 
2.25 ml 
(6 doses) 
2.25 ml 
(6 doses) 
2.25 ml 
(6 doses) 
2.25 ml 
(6 doses) 
0.4 ml (10 
doses) 
1.3 ml 
(10 doses) 
1.3 ml 
(10 doses) 
195 multidose 
vials 
(1170 doses)  
10 multidose 
vials 
(60 doses)  
195 multidose 
vials 
(1170 doses)  
10 multidose 
vials 
(100 doses)  
195 multidose 
vials 
(1950 doses)  
10 multidose 
vials 
(60 doses)  
195 multidose 
vials 
(1170 doses)  
10 multidose 
vials 
(60 doses)  
195 multidose 
vials 
(1170 doses)  
10 multidose 
vials 
(100 doses)  
10 multidose 
vials 
(100 doses)  
195 multidose 
vials 
(1950 doses)  
1/5 
 
 
 
EU/1/20/1528/013  COMIRNATY   
--2 
EU/1/20/1528/014  COMIRNATY  
--5 
EU/1/20/1528/015  COMIRNATY  
--8 
Original/Omicron 
BA.4-5 
Original/Omicron 
BA.4-5 
EU/1/20/1528/016  COMIRNATY 
--8  
EU/1/20/1528/017  COMIRNATY 
--9 
Original/Omicron 
BA.4-5  
EU/1/20/1528/018  COMIRNATY 
--10 
Original/Omicron 
BA.4-5 
EU/1/20/1528/019  COMIRNATY 
--10 
Omicron 
XBB.1.5  
EU/1/20/1528/020  COMIRNATY 
--10 
Omicron 
XBB.1.5  
EU/1/20/1528/021  COMIRNATY 
--11 
Omicron 
XBB.1.5  
EU/1/20/1528/022  COMIRNATY 
--12 
Omicron 
XBB.1.5 
Omicron 
XBB.1.5 
EU/1/20/1528/023  COMIRNATY 
--12  
EU/1/20/1528/024  COMIRNATY 
--13 
Omicron 
XBB.1.5 
Omicron 
XBB.1.5 
Dispersion for 
injection 
Intramuscular 
use 
Dispersion for 
injection 
Intramuscular 
use 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
0.48 ml (1 dose)  10 single dose 
vials 
(10 doses)  
vial (glass) 
0.48 ml (1 dose)  10 single dose 
vials 
(10 doses)  
vial (glass) 
0.48 ml (1 dose)  10 single dose 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
Concentrate for 
dispersion for 
injection 
Dispersion for 
injection 
Intramuscular 
use 
Intramuscular 
use 
vial (glass) 
2.25 ml 
(6 doses) 
0.4 ml 
(10 doses) 
vials 
(10 doses)  
10 multidose 
vials 
(60 doses)  
10 multidose 
vials 
(100 doses)  
vial (glass) 
0.48 ml (1 dose)  10 single dose 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
2.25 ml 
(6 doses) 
2.25 ml 
(6 doses) 
Intramuscular 
use 
vial (glass) 
1.3 ml 
(10 doses) 
Concentrate for 
dispersion for 
injection 
Dispersion for 
injection 
Dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
Concentrate for 
dispersion for 
injection 
Intramuscular 
use 
vial (glass) 
2.25 ml 
(6 doses) 
0.4 ml 
(10 doses) 
Intramuscular 
use 
vial (glass) 
0.48 ml (1 dose)  10 single dose 
vials 
(10 doses)  
10 multidose 
vials 
(60 doses)  
195 multidose 
vials 
(1170 doses)  
10 multidose 
vials 
(100 doses)  
vials 
(10 doses)  
10 multidose 
vials 
(60 doses)  
10 multidose 
vials 
(100 doses)  
--1: COMIRNATY 30 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/001): 
After dilution, 1 dose (0.3 mL) contains 30 micrograms of tozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). 
2/5 
 
 
 
 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
--2: COMIRNATY 30 micrograms/dose dispersion for injection (EU/1/20/1528/002-003, EU/1/20/1528/013): 
1 dose (0.3 mL) contains 30 micrograms of tozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles).  
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
--3: COMIRNATY 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/004-005) 
After dilution, 1 dose (0.2 mL) contains 10 micrograms of tozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
--4: COMIRNATY Original/Omicron BA.1 (15/15 micrograms)/dose dispersion for injection (EU/1/20/1528/006-007): 
1 dose (0.3 mL) contains 15 micrograms of tozinameran and 15 micrograms riltozinameran, COVID-19 mRNA Vaccine (embedded in 
lipid nanoparticles). 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
Riltozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron BA.1). 
--5: COMIRNATY Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection (EU/1/20/1528/008-009, 
EU/1/20/1528/014): 
1 dose (0.3 mL) contains 15 micrograms of tozinameran and 15 micrograms famtozinameran, COVID-19 mRNA Vaccine (embedded in 
lipid nanoparticles). 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
Famtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron BA.4-5). 
--6: COMIRNATY 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/010) 
After dilution, 1 dose (0.2 mL) contains 3 micrograms of tozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
--7: COMIRNATY Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection (EU/1/20/1528/011-012) 
After dilution, 1 dose (0.2 mL) contains 5 micrograms of tozinameran and 5 micrograms famtozinameran, COVID-19 mRNA Vaccine 
(embedded in lipid nanoparticles). 
3/5 
 
 
 
 
 
 
 
 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
Famtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron BA.4-5). 
--8: COMIRNATY Original/Omicron BA.4-5 (5/5 micrograms)/dose dispersion for injection (EU/1/20/1528/015-016): 
1 dose (0.3 mL) contains 5 micrograms of tozinameran and 5 micrograms famtozinameran, COVID-19 mRNA Vaccine (embedded in lipid 
nanoparticles). 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
Famtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron BA.4-5). 
--9: COMIRNATY Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection (EU/1/20/1528/017) 
After dilution, 1 dose (0.2 mL) contains 1.5 micrograms of tozinameran and 1.5 micrograms famtozinameran, COVID-19 mRNA Vaccine 
(embedded in lipid nanoparticles). 
Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Original). 
Famtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron BA.4-5). 
--10: COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection (EU/1/20/1528/018-020): 
1 dose (0.3 mL) contains 30 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles).  
Raxtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5). 
--11: COMIRNATY Omicron XBB.1.5 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/021) 
After dilution, 1 dose (0.2 mL) contains 10 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). 
Raxtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5). 
--12: COMIRNATY Omicron XBB.1.5 10 micrograms/dose dispersion for injection (EU/1/20/1528/022-023): 
1 dose (0.3 mL) contains 10 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles).  
Raxtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5). 
--13: COMIRNATY Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/024) 
After dilution, 1 dose (0.2 mL) contains 3 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). 
4/5 
 
 
 
 
 
 
 
 
Raxtozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the 
corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5). 
5/5 
 
 
 
 
